{"id":1599,"date":"2024-12-23T19:34:07","date_gmt":"2024-12-23T10:34:07","guid":{"rendered":"https:\/\/c-mng.cwh.hokudai.ac.jp\/gcb.med\/JP\/?p=1599"},"modified":"2024-12-23T19:54:01","modified_gmt":"2024-12-23T10:54:01","slug":"report_0219seminar","status":"publish","type":"post","link":"https:\/\/c-mng.cwh.hokudai.ac.jp\/gcb.med\/JP\/eventslist\/report_0219seminar.html","title":{"rendered":"\u3010\u304a\u77e5\u3089\u305b\u30112\/19_GCB Special Seminar\u958b\u50ac\u306e\u3054\u6848\u5185"},"content":{"rendered":"
2025\u5e742\u670819\u65e5(\u6c34)\u3001\u5317\u6d77\u9053\u5927\u5b66\u533b\u5b66\u90e8\u81e8\u5e8a\u5927\u8b1b\u5802\u306b\u3066\u300cGCB Special Seminar\u300d\u3092\u958b\u50ac\u3044\u305f\u3057\u307e\u3059\u3002<\/p>
\u4eca\u56de\u306f\u533b\u5b66\u7269\u7406\u5b66\u306e\u6a29\u5a01\u3067\u3042\u308b\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66\u306eLei Xing\u6559\u6388\u3001\u540c\u3058\u304f\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66\u306e\u653e\u5c04\u7dda\u816b\u760d\u5b66\u81e8\u5e8a\u51c6\u6559\u6388Michael Gensheimer\u5148\u751f\u306e\u304a\u4e8c\u65b9\u3092\u8b1b\u5e2b\u3068\u3057\u3066\u304a\u62db\u304d\u3057\u3066\u304a\u308a\u307e\u3059\u3002Gensheimer\u5148\u751f\u306f\u3001\u672c\u5b66\u304c\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66\u3068\u884c\u3063\u305f\u56fd\u969b\u5171\u540c\u81e8\u5e8a\u8a66\u9a13\u300cAblative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial\uff08\u80ba\u816b\u760d\u3078\u306e\u4f53\u5e79\u90e8\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\uff1a\u7b2c2\u76f8\u975e\u30e9\u30f3\u30c0\u30e0\u5316\u524d\u5411\u304d\u8a66\u9a13\uff09\u300d\uff08DOI\uff1a10.1001\/jamaoncol.2023.3495\uff09\u306e\u7b46\u982d\u8457\u8005\u3067\u3001\u4eca\u56de\u521d\u3081\u3066\u672c\u5b66\u306b\u3054\u6765\u8a2a\u3055\u308c\u307e\u3059\u3002<\/p>
\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66\u306e\u6700\u5148\u7aef\u306e\u7814\u7a76\u6210\u679c\u3084\u53d6\u7d44\u306b\u3064\u3044\u3066\u3054\u8b1b\u6f14\u3044\u305f\u3060\u304d\u307e\u3059\u306e\u3067\u3001\u305c\u3072\u3068\u3082\u4f1a\u5834\u306b\u304a\u8d8a\u3057\u9802\u304d\u3001Xing\u5148\u751f\u3001Gensheimer\u5148\u751f\u306e\u304a\u8a71\u3092\u76f4\u63a5\u4f1a\u5834\u3067\u3054\u8074\u8b1b\u304f\u3060\u3055\u3044\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u307f\u306a\u3089\u305a\u3001\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66\u533b\u5b66\u90e8\u306e\u7814\u7a76\u306b\u8208\u5473\u306e\u3042\u308b\u65b9\u3001\u533b\u5b66\u751f\u3001\u521d\u671f\u7814\u4fee\u533b\u306e\u7686\u69d8\u306e\u3054\u6765\u5834\u3092\u304a\u5f85\u3061\u3057\u3066\u304a\u308a\u307e\u3059\u3002<\/p>
\u8a73\u7d30\u306b\u3064\u304d\u307e\u3057\u3066\u306f\u3001\u4e0b\u8a18\u30dd\u30b9\u30bf\u30fc\u3092\u3054\u53c2\u7167\u304f\u3060\u3055\u3044\u3002<\/p>